2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06C.03 Clinicopathological Analysis of Each EGFR Status in Surgically Resected Lung Adenocarcinoma: A Real-World Study (CReGYT-01 EGFR)

EP.06C.03 Clinicopathological Analysis of Each EGFR Status in Surgically Resected Lung Adenocarcinoma: A Real-World Study (CReGYT-01 EGFR)

Back to course

Pdf Summary

The study led by Hironobu Hoshino aimed to elucidate the clinicopathological characteristics associated with different EGFR (epidermal growth factor receptor) mutational subtypes in surgically resected lung adenocarcinoma patients. This real-world study, known as CReGYT-01 EGFR, employed data from patients who underwent radical resection of lung adenocarcinoma between January 2015 and November 2018, resulting in a final dataset involving 2,580 patients. Variables analyzed included patient demographics (age, sex, smoking status), pathological features (subtype predominance, IASLC grade), and EGFR status (wild type vs. mutated, including common mutations like L858R and 19del, as well as uncommon mutations).<br /><br />Key findings indicated varied biological characteristics among EGFR mutational subtypes. Notably, the study found distinct clinicopathological patterns between the L858R and 19del mutations. The L858R mutation exhibited a higher prevalence of ground-glass opacity (GGO) and lepidic predominant patterns, suggesting a less aggressive pathological phenotype compared to the 19del mutation, which was associated with more invasive characteristics.<br /><br />The study is significant as it is one of the first to analyze the correlation of EGFR mutational status with the IASLC grading system, which evaluates pathological invasiveness. Such insights can contribute to the tailored treatment strategies and improved prognostic assessments for lung adenocarcinoma patients based on their EGFR status. The findings suggest that the IASLC grading system can be effectively applied to stratify lung adenocarcinoma cases with EGFR mutations, enhancing the understanding of tumor behavior and aiding in clinical decision-making. Overall, this investigation highlights the importance of EGFR subtype identification in the context of lung adenocarcinoma prognosis and treatment strategy refinement.

Asset Subtitle

HIRONOBU HOSHINO

Meta Tag

Speaker HIRONOBU HOSHINO

Topic Pathology and Biomarkers

Keywords

EGFR mutations

lung adenocarcinoma

clinicopathological characteristics

L858R mutation

19del mutation

IASLC grading system

ground-glass opacity

lepidic pattern

tumor invasiveness

treatment strategies